N
Nurix Therapeutics Inc (NRIX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$14.73
-0.75 (-4.84%)
Market Cap: $1.69B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nurix Therapeutics Inc (NRIX) P/E Ratio & Valuation Multiples
Nurix Therapeutics (NRIX) trades at 6.4x trailing earnings and 2.3x sales. Its P/S of 2.3x is below its 5-year median of 15.1x.
Current Multiples
Its enterprise value is 3.1x its EBITDA. Its free cash flow yield is 22.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 6.4x |
| Forward P/E | N/A |
| Price to sales | 2.3x |
| Price to book | 1.7x |
| EV/EBITDA | 3.1x |
| Price to FCF | 4.4x |
| EV/FCF | 2.5x |
| PEG | N/A |
| FCF yield | 22.5% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.3x | 15.1x | N/A |
| P/B | 1.7x | 2.5x | N/A |
Valuation History
Over the 6 year ends shown, its P/S ranged from 7.3x in 2023 to 48.9x in 2020.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $18.97 | 19.3x | 3.3x |
| 2024 | $18.84 | 22.5x | 2.8x |
| 2023 | $10.32 | 7.3x | 2.8x |
| 2022 | $10.98 | 13.6x | 2.0x |
| 2021 | $28.95 | 42.1x | 3.8x |
| 2020 | $32.88 | 48.9x | 4.4x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NRIX
Is NRIX stock overvalued?
GNG's valuation label for NRIX is Undervalued.
What is NRIX's price to sales ratio?
Nurix Therapeutics has a price to sales ratio of 2.3x.
NRIX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors